PAC3 signs exclusive agreement with Bioton.
PAC3 signs exclusive agreement with Bioton for Gensulin (Recombinant Human Insulin) in vials and cartridges as well as Gensupen range of products in Malta.
Insulin is a preparation for use in diabetes therapy. It is not a drug that cures the source of the disease but only a substitute for the hormone, which is lacking or unavailable to the cells of the patient’s organism.
Type 1 diabetes results from the genetic, inborn damage to the beta cells in the pancreas, responsible for insulin production. The symptoms of the disease derive from a deficiency or a complete lack of endogenous insulin. Diabetes of this type emerges in childhood or in adolescence and involves the administration of insulin for the whole life. Dosage of the preparation for these patients is usually average. Life expectancy measured from the start of the therapy is between 50-60 years.
Type 2 diabetes usually emerges in patients after the age of 40 and is related to eating habits and obesity. Patients from this group begin their therapy with drugs administered orally and after a period of time the progress of the disease forces many of them to use insulin, initially with small and gradually increasing to very high doses. In diabetes of this type there is no insulin deficiency. Its essential characteristic is the fact that tissue vulnerability to this hormone is steadily fading. The phenomenon, which is called insulin resistance, leads to the consumption of huge doses of exogenous insulin by patients with advanced phases of the disease.
Human insulin – a product obtained by a technology based on the achievements of genetic engineering. Bacteria or fungi where the human insulin-coding gene has been introduced, produce this hormone in a fermentation process. The product obtained is identical to insulin produced by the human pancreas. Human insulin is a breakthrough in the treatment of diabetes, allowing an improvement in the comfort of life and prognosis for patients with both types of diabetes.